HER2-Low Breast Cancer: Pathological and Clinical LandscapePaolo Tarantino, Giuseppe Curigliano, Erika Hamilton et al.|Journal of Clinical Oncology|2020Cited by 801
Targeting the microenvironment in solid tumorsCarmen Belli, Giuseppe Curigliano, Dario Trapani et al.|Cancer Treatment Reviews|2018Cited by 516
Recent advances in triple negative breast cancer: the immunotherapy eraAntonio Marra, Giuseppe Curigliano, Giulia Viale|BMC Medicine|2019Cited by 378
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesAntonio Marra, Giuseppe Curigliano, Dario Trapani et al.|npj Breast Cancer|2020Cited by 319
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP. Tarantino, G. Curigliano, Giulia Viale et al.|Annals of Oncology|2023Cited by 298